Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension

Objective: The goal of this multicenter, double-blind, randomized, parallel-group study was to compare the effects of losartan potassium (hereafter referred to as losartan), candesartan cilexitil (hereafter referred to as candesartan), and losartan/hydrochlorothiazide (HCTZ) in patients with mild to...

Full description

Saved in:
Bibliographic Details
Published in:Clinical therapeutics 2000-10, Vol.22 (10), p.1186-1203
Main Authors: Manolis, Athanasios J, Grossman, Ehud, Jelakovic, Bojan, Jacovides, Andrew, Bernhardi, David C, Cabrera, Walter J, Watanabe, Luis A, Barragan, Jaime, Matadamas, Norberto, Mendiola, Alfred, Woo, K.S, Zhu, Jun R, Mejia, Agnes D, Bunt, Ton, Dumortier, Thomas, Smith, Ronald D
Format: Article
Language:English
Subjects:
angiotensin II antagonist
Antihypertensive agents
antihypertensive therapy
Biological and medical sciences
candesartan hydrochlorothiazide
Cardiovascular system
losartan
Medical sciences
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: The goal of this multicenter, double-blind, randomized, parallel-group study was to compare the effects of losartan potassium (hereafter referred to as losartan), candesartan cilexitil (hereafter referred to as candesartan), and losartan/hydrochlorothiazide (HCTZ) in patients with mild to moderate hypertension (sitting diastolic blood pressure [(SiDBP] 95–115 mm Hg). Methods: A total of 1161 patients were randomized in a 2:2:1 ratio to 12 weeks of treatment with losartan 50 mg QD, possibly titrated to 100 mg QD (n = 461); candesartan 8 mg QD, possibly titrated to 16 mg QD (n = 468); or losartan 50 mg QD, possibly titrated to losartan 50 mg plus HCTZ 12.5 mg QD (n = 232). At 6 weeks, the regimens of patients not reaching a goal SiDBP
ISSN:0149-2918
1879-114X
DOI:10.1016/S0149-2918(00)83062-3